Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 8 examiners • 0 of 9 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Shionogi & Co., Ltd. currently has 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 8 distinct examiners. With 9 pending actions and 8 examiners, the portfolio shows a distribution of work across the assigned personnel. This suggests that the company's prosecution efforts are spread across a group of examiners rather than concentrated in a few hands.
The portfolio's activity is further distributed across 5 distinct art units. The presence of 5 art units for 9 pending actions indicates that Shionogi's pharmaceutical developments span several different specialized areas within the patent office. CHAO, ALLEN is the busiest examiner for the company, currently managing 2 pending office actions. The remaining examiners are each responsible for the other pending matters, ensuring a spread of examiner interactions that requires managing various individual perspectives during the prosecution process.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 4 (44%) |
| No statute on record | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHAO, ALLEN | 2 | 55.6% | +0.0% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| ALLEN, MICHAEL D | 1 | 32.0% | +49.4% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| KAUFMAN, CLAIRE M | 1 | 63.5% | +50.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 2d overdue |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 30d |
| 18729630 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | OH, TAYLOR V | — |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 2d overdue |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 30d |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 84d |
| 18729630 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | OH, TAYLOR V | — |
| 18755191 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | MOORE, SUSANNA | — |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1671 | 1 |
| 1622 | 1 |
| 1617 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891180 | PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF | CHAO, ALLEN | — | DP | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 1625 | — | Final Rejection | 84d | Pending | Aug 22, 2024 |
| 18729630 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | OH, TAYLOR V | — | §102§103§112 | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18755191 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | MOORE, SUSANNA | — | §112DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | GONZALEZ, LUISALBERTO | — | §102§112 | Non-Final OA | — | Pending | May 20, 2024 |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 1671 | §102§103§112 | Non-Final OA | 2d overdue | Pending | Aug 25, 2023 |
| 18335687 | DIHYDROOXADIAZINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | CHAO, ALLEN | 1622 | §112 | Final Rejection | 9d | Pending | Jun 15, 2023 |
| 18007119 | LYOPHILIZED FORMULATION CONTAINING CEPHALOSPORIN HAVING CATECHOL GROUP AND THE MANUFACTURING METHOD | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 27d | Pending | Jan 27, 2023 |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 1674 | §102§112Other | Non-Final OA | 30d | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial